BISPECIFIC ANTIBODY FOR ICOS AND PD-L1

Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and...

Full description

Saved in:
Bibliographic Details
Main Authors MCCOURT, Matthew John, TUNA, Mihriban, WOLLERTON VAN HORCK, Francisca, ARKINSTALL, Stephen John, BADR, Fadi, FIEHLER, Ryan, CAMPBELL, Jamie Iain, AKELE, Frederik, SAINSON, Richard Charles Alfred, FAROUDI, Mustapha
Format Patent
LanguageEnglish
French
German
Published 28.10.2020
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.
Bibliography:Application Number: EP20180829933